News articles about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.893009908467 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Taro Pharmaceutical Industries (NYSE TARO) opened at 105.57 on Friday. Taro Pharmaceutical Industries has a one year low of $92.28 and a one year high of $125.87. The firm has a market cap of $4.27 billion, a P/E ratio of 10.75 and a beta of 0.65. The stock’s 50 day moving average is $105.69 and its 200-day moving average is $111.90.

A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. TheStreet upgraded shares of Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Thursday, July 20th. Finally, Credit Suisse Group downgraded shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a report on Tuesday, May 23rd.

COPYRIGHT VIOLATION NOTICE: “Taro Pharmaceutical Industries (TARO) Earns News Sentiment Rating of 0.20” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Insider Buying and Selling by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with's FREE daily email newsletter.